HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Should Consider Pearson Model for Qualified Claims– NNFA

This article was originally published in The Tan Sheet

Executive Summary

FDA needs to explore testing more specific, expanded qualified health claims language as suggested in the Pearson vs. Shalala decision, according to the National Nutritional Foods Association

You may also be interested in...



Qualified Health Claim Testing May Draw On FTC Study Findings

FDA may look to health claim statements developed and tested by FTC as it continues working toward effective use of the claims in product labeling, Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD, indicated during a recent speech to industry

Qualified Health Claims Research Supports Moratorium On Claims – CSPI

"FDA should rescind its approval of all qualified health claims and impose a moratorium on the approval of additional qualified claims" that do not meet significant scientific agreement standards, the Center for Science in the Public Interest argued following a presentation of consumer research on health claims

Lawsuit Will Question Supplement Exclusion From Lycopene/Cancer Claims

American Longevity will file a lawsuit against FDA no later than Dec. 9 in response to the agency's denial of qualified health claims tying lycopene-containing dietary supplements to cancer risk reduction

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS126090

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel